Navigation Links
OrbusNeich's Genous(TM) Bio-Engineered R Stent(TM) is Subject of Sessions on Innovation at TCT 2007
Date:10/17/2007

Latest Randomized Clinical Trial Results of First Pro-Healing Stent Also

Featured at Annual Symposium

HONG KONG, Oct. 18 /PRNewswire/ -- OrbusNeich's Genous(TM) Bio-engineered R stent(TM) is the subject of several sessions about innovation in interventional cardiology strategies and device design at this year's Transcatheter Cardiovascular Therapeutics symposium, TCT 2007, which is set for Oct. 20-25 at the Washington Convention Center in Washington, D.C.

The line-up of sessions that feature the first pro-healing stent, which is an alternative to drug-eluting stents, includes:

- Interventional Strategies and Adjunct Pharmacology in ACS and AMI;

Should Specialized DES for AMI be Developed? Early Experience with EPC

Capture Technology; Jan Henk Dambrink, M.D., Ph.D., Department of

Cardiology, ISALA Klinieken, Hospital De Weezenlanden, Zwolle, The

Netherlands; 2:10 p.m. EDT on Oct. 21; Room 151B

- Innovative Devices and Futuristic Concepts: Novel Bare Metal and Drug-

Eluting Stents; The Genous Stent Coating with CD34 Antibodies to

Actively Capture Circulating EPCs: Design Parameters and Effects on

Healing and Thrombogenicity; Michael Kutryk, M.D., clinician scientist

and interventional cardiologist at St. Michael's Hospital, assistant

professor at the University of Toronto; Canada; 3:08 p.m. EDT on Oct.

21; Room 152A

In addition, the latest results from clinical trials of the Genous stent will be discussed by Robbert de Winter, M.D., Ph.D., principal investigator and director of the catheterization laboratory at the Academic Medical Center in Amsterdam. Specifically, de Winter will present:

- Updates from the HEALING studies, AMC "Real World" registry and TRIAS

trial; 4:36 p.m. EDT on Oct. 21; Ballroom C, 3rd floor

- A late-breaking report of six-month clinical outcomes from the TRIAS HR

pilot study: a prospective, randomized trial comparing the Genous stent

and a paclitaxel-eluting stent in lesions at high risk for restenosis;

12:45 p.m. EDT on Oct. 22; Main Arena

Unlike drug-eluting stents, Genous, which is coated with an antibody, captures a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process. EPCs circulate in the bloodstream and are involved in the repair of blood vessels. When attracted to the surface of Genous, EPCs rapidly form an endothelial layer over the stent that provides protection against thrombus and minimizes restenosis.

OrbusNeich designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. The company's product portfolio includes the Genous(TM) Bio-engineered R stent(TM), an antibody- coated device that is the first-ever stent to capture a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process following placement. Other products are stents, balloons and guiding catheters marketed under the names of Blazer(TM), R stent(TM), Sapphire(TM), Avita(TM), Avita HP(TM), SafeCut(TM), Lumina(TM) and Saffron.

A global company, OrbusNeich is headquartered in Hong Kong and has operations in Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Shenzhen, China. OrbusNeich, which has provided cardiology devices to physicians through its predecessor companies since 1979, today supplies products in more than 60 countries. For more information, visit http://www.OrbusNeich.com.


'/>"/>
SOURCE OrbusNeich
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Efficacy of OrbusNeichs Genous Bio-Engineered R Stent Compares Favorably to Drug-Eluting Stents
2. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
3. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
4. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
5. Lux Biosciences Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
6. Pharmathenes Recombinant Butyrylcholinesterase (rBChE) Program the Subject of Promising New Alzheimers Research
7. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) Program the Subject of Promising New Alzheimers Research
8. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
9. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
10. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
11. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... 2016 Research and Markets has announced ... to 2021" report to their offering. ... Market growth can ... in the pharmaceutical and biotechnology industry and technological advancements like ... Emerging markets and growing research activities in toxicology and stem ...
(Date:12/9/2016)... 9, 2016 Research and Markets has announced ... report to their offering. ... The global travel vaccines market to grow at a ... covers the present scenario and the growth prospects of the global ... report considers the revenue generated from the sales of various vaccines ...
(Date:12/8/2016)... LONDON , Dec. 8, 2016 Australia ... GlobalData,s new report, "Australia Ophthalmic Lasers Market Outlook to ... Lasers market. The report provides value, in millions of ... within market segements - Excimer Lasers, Femtosecond Lasers and ... and distribution shares data for each of these market ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... 08, 2016 , ... Mirixa Corporation , a leading ... pharmacist-delivered patient care services, has announced the promotions of Karen Litsinger to senior ... of sales. , Litsinger joined Mirixa in 2008 after serving as a ...
(Date:12/8/2016)... Boston (PRWEB) , ... December 08, 2016 , ... ... shareholders with global law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. ... sponsor of the DeviceTalks series, and attorneys from the firm’s global Life Sciences & ...
(Date:12/8/2016)... , ... December 08, 2016 ... ... Suite 10.2 version gives development continuity to its innovative Unified Instance Manager ... management capacity. In addition, this new version optimizes the unattended auto-dialing system ...
(Date:12/8/2016)... , ... December 08, 2016 , ... STAT courier is ... be a convenient service for Texas, they are expanding their presence in Dallas. One ... hiring spree that will bring new jobs to the Dallas and Forth Worth market. ...
(Date:12/8/2016)... Charlotte, NC (PRWEB) , ... December 08, 2016 ... ... repeal Medicare and the Affordable Care Act. Dr. Botelho advocates for the mass ... A story movement gives people ongoing opportunities to share their unfortunate experiences; such ...
Breaking Medicine News(10 mins):